Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Characterization of the Binding of [3H][Dmt1]H-Dmt-d-Arg-Phe-Lys-NH2, a Highly Potent Opioid Peptide

Claire L. Neilan, Adam J. Janvey, Elizabeth Bolan, Irena Berezowska, Thi M.-D. Nguyen, Peter W. Schiller and Gavril W. Pasternak
Journal of Pharmacology and Experimental Therapeutics August 2003, 306 (2) 430-436; DOI: https://doi.org/10.1124/jpet.103.049742
Claire L. Neilan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam J. Janvey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Bolan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irena Berezowska
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thi M.-D. Nguyen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter W. Schiller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gavril W. Pasternak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The dermorphin-derived peptide [Dmt1]DALDA (H-Dmt-d-Arg-Phe-Lys-NH2; Dmt, 2′,6′-dimethyltyrosine) labels μ-opioid receptors with high affinity and selectivity in receptor binding assays. In previous studies, [Dmt1]DALDA displayed a mechanism of action distinct from that of morphine, as evidenced by its insensitivity to antisense probes reducing morphine analgesia and incomplete cross tolerance to morphine. In an effort to further elucidate the unusual mechanism of action, [3H][Dmt1]DALDA has been synthesized and its binding profile studied. [3H][Dmt1]DALDA binding was high affinity (KD = 0.22 nM) and showed a regional distribution consistent with μ-receptors with highest levels in calf striatal membranes. [3H][Dmt1]DALDA binding was far less sensitive than [3H][d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) to the effects of divalent and sodium cations and guanine nucleotides, although NaCl and guanosine 5′-(β,γ-imido)triphosphate together reduced specific [3H][Dmt1]DALDA binding levels by almost 75%. Competition studies confirmed the μ-selectivity of the binding, with Ki values that were not appreciably different from those seen against [3H]DAMGO. In guanosine 5′-O-(3-[35S]thio)-triphosphate ([35S]GTPγS) binding assays in brain and spinal cord membranes, [Dmt1]DALDA was more potent than DAMGO, but showed plateaus suggestive of a partial agonist. [Dmt1]DALDA bound to μ-opioid receptor clone 1 (MOR-1) and its splice variants with high affinity. Unlike [3H]DAMGO, [3H][Dmt1]DALDA seemed to label both agonist and antagonist conformations of MOR-1 expressed in Chinese hamster ovary cells. In [35S]GTPγS assays [Dmt1]DALDA showed high efficacy with all the MOR-1 variants, but its potency (EC50) varied markedly among some of the splice variants despite similar affinities in receptor binding assays. Although [3H][Dmt1]DALDA is a very potent μ-selective analgesic, its binding characteristics and its ability to stimulate GTPγS binding differed from that of the classical μ-opioid peptide DAMGO.

Footnotes

  • This work was supported, in part, by Grants DA02615 and DA07242 and a Senior Scientist Award (DA00220) to G.W.P. from the National Institute on Drug Abuse, a core grant from the National Cancer Institute (CA08748) to MSKCC and a Program Project Grant (P01-DA08924) to P.W.S.

  • DOI: 10.1124/jpet.103.049742.

  • ABBREVIATIONS: M6G, morphine-6β-glucuronide; MOR-1, μ-opioid receptor clone-1; [Dmt1]DALDA, H-Dmt-d-Arg-Phe-Lys-NH2; Dmt, 2′,6′-dimethyltyrosine; DAMGO, [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin; CHO, Chinese hamster ovary; GTPγS, guanosine 5′-O-(3-thio)triphosphate; Gpp(NH)p, guanosine 5′-(β,γ-imido)triphosphate; HEK, human embryonic kidney; U50,488H, (trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide methane-sulfonate hydrate; CTAP, d-Phe-c[Cys-Tyr-d-Trp-Arg-Thr-Pen]-Thr-NH2.

    • Received January 30, 2003.
    • Accepted March 25, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 306 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 306, Issue 2
1 Aug 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Characterization of the Binding of [3H][Dmt1]H-Dmt-d-Arg-Phe-Lys-NH2, a Highly Potent Opioid Peptide
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Characterization of the Binding of [3H][Dmt1]H-Dmt-d-Arg-Phe-Lys-NH2, a Highly Potent Opioid Peptide

Claire L. Neilan, Adam J. Janvey, Elizabeth Bolan, Irena Berezowska, Thi M.-D. Nguyen, Peter W. Schiller and Gavril W. Pasternak
Journal of Pharmacology and Experimental Therapeutics August 1, 2003, 306 (2) 430-436; DOI: https://doi.org/10.1124/jpet.103.049742

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Characterization of the Binding of [3H][Dmt1]H-Dmt-d-Arg-Phe-Lys-NH2, a Highly Potent Opioid Peptide

Claire L. Neilan, Adam J. Janvey, Elizabeth Bolan, Irena Berezowska, Thi M.-D. Nguyen, Peter W. Schiller and Gavril W. Pasternak
Journal of Pharmacology and Experimental Therapeutics August 1, 2003, 306 (2) 430-436; DOI: https://doi.org/10.1124/jpet.103.049742
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Iclepertin (BI 425809) in schizophrenia-related models
  • D1 agonist vs. methylphenidate on PFC working memory
  • Obesity Thwarts Preconditioning in TBI
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics